July 2025 in “Ultrasound in Medicine & Biology” This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.
October 2014 in “Cancer research” This study found that targeting mTORC1 with rapamycin effectively inhibited skin tumor promotion in a mouse model, highlighting a potential target for cancer chemoprevention.
April 2012 in “Cancer research” In this study, the authors found that targeting mTORC1 with rapamycin inhibited TPA-induced skin tumor promotion by affecting keratinocyte proliferation, including critical stem cell populations in the mouse epidermis.
September 2026 in “International Journal of Nanomedicine” This review discusses the potential of combining microneedle systems with exosome-based therapeutics to enhance delivery efficiency and overcome current challenges, reporting no new experimental findings.
1 citations
,
April 2023 in “International Journal of Molecular Sciences” This review discusses advances in CRISPR/Cas9 variants and nanoformulations for cancer treatment, noting challenges and prospects for clinical application, but reports no new research results.